Chondroitin Sulfate in the Management of Hip and Knee Osteoarthritis: An Overview

Advances in Pharmacology

Volumn 53, Issue , 2006, Pages 507-522

  Bana, Géraldine ^a   Jamard, Bénédicte ^b   Verrouil, Evelyne ^b   Mazières, Bernard ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE;

ARTHRALGIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ARTHRALGIA; CHONDROITIN SULFATES; HUMANS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; RANDOMIZED CONTROLLED TRIALS;

EID: 33846143213     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(05)53026-6     Document Type: Review

References (48)

1. Aleekseeva L.I., Benevolenskaia L.I., Nasonov E.L., Chichasova N.V., and Kariakin A.N. Structum (chondroitin sulfate): A new agent for the treatment of osteoarthritis. Ter. Arkh. 71 (1999) 51-53
2. Alekseeva L.I., Arkhangel'skaia G.S., Davydova A.F., Karmil'tseva E.A., Kogan K.M., Mazurov V.I., Rebrov A.P., Riabitseva O.F., Shemerovskaia T.G., and Lakushin S.S. Long-term effects of structum administration (according to data from multicenter trial). Ter. Arkh. 75 (2003) 82-86
3. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 43 (2000) 1905-1915
4. European multicenter study on effectiveness of chondroitin sulfate in gonarthrosis: A new look at biochemical and radiologic result. Anonymous. Presse Med. 29 Suppl. 27 (2002) 15-18
5. Avouac B., and Dropsy R. Méthodologie des essais thérapeutiques des médicaments de base de l'arthrose. Thérapie 48 (1993) 315-319
6. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., and Stitt L.W. Validation of WOMAC: A health status instrument for measuring clinically important patent relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or the knee. J. Rheumatol. 15 (1988) 1833-1840
7. Bourgeois P., Chales G., Dehais J., Delcambre B., Kuntz J.L., and Rozemberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage 6 Suppl. A (1998) 25-30
8. Bucsi L., and Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSDOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 6 Suppl. A (1998) 31-36
9. Chalmers T.C., Smith Jr. H., Blackburn B., Silverman B., Schroeder B., Reitman D., and Ambroz A. A method for assessing the quality of a randomized control trial. Control Clin. Trials 2 (1981) 31-49
10. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., Bradley J.D., Bingham III C.O., Weisman M.H., Jackson C.G., Lane N.E., Cush J.J., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 354 (2006) 795-808
11. Cohen J. "Statistical Power Analysis for the Behavioral Sciences,". 2nd Ed (1988), Lawrence Erlbaum Association, Hillsdale, NJ
12. Cohen M., Wolfe R., Mai T., and Lewis D. A randomized, double blind, placebo controlled trial of the topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J. Rheumatol. 30 (2003) 523-528
13. Committee for Proprietary Medicinal Products. "Points to Consider on Clinical Investigation of Medicinal Products Used in the Treatment of Osteoarthritis." (1998), European Agency for the Evaluation of Medicinal Products, London, UK
14. Conrozier T. Anti-arthrosis treatments: Efficacy and tolerance of chondroitin sulfate (CS 4 & 6). Presse Med. 27 (1998) 1862-1865
15. Das Jr. A., and Hammad T.A. Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of the knee osteoarthritis. Osteoarthritis Cartilage 8 (2000) 343-350
16. Debi R., Robinson D., Agar G., and Halperin N. GAG for osteoarthritis of the knee: A prospective study. Harefuah 138 (2000) 451-453
17. Food and Drug Administration. Guidance for Industry: Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis. FDA document 07/1999 (1999), Food and Drug Administration, Washington, DC
18. Group for Management of Osteoarthritis. Special meeting on osteoarthritis. Rev. Rhum. Mal. Osteoartic. 57 9bis (1990) 1S-50S
19. Huskisson E.C. Measurement of pain. J. Rheumatol. 9 (1982) 768-769. http://nccam.nih.gov/news/19972000/121100/qa.htm#1
20. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W.J., Dieppe P., Gunther K., Hauselmann H., Herrero-Beaumont G., Kaklamanis P., Lohmander S., Leeb B., et al. EULAR recommendations 2003, an evidence based approach to the management of knee osteoarthritis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. Ann. Rheum. Dis. 62 (2003) 1145-1155
21. Kerzberg E.M., Roldan E.J.A., Castelli G., and Hubermann E.D. Combination of a glycosaminoglycans and acetylsalicylic acid in knee osteoarthritis. Scand. J. Rheumatol. 16 (1987) 377-380
22. L'Hirondel J.L. Etude clinique en double insu du sulfate de chondroïtine per os versus placebo dans la gonarthrose fémoro-tibiale (125 patients). Litera Rheumatol. 14 (1992) 77-85
23. Leeb B., Schweitzer H., Montag K., and Smolen J. A metaanalysis of chondroïtine sulphate in the treatment of osteoarthritis. J. Rheumatol. 27 1 (2000) 205-211
24. Leffler C.T., Philippi A.F., Leffler S.G., Mosure J.C., and Kim P.D. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint desease of the knee or low back: A randomized, double-blind, placebo-controlled pilot study. Mil. Med. 164 (1999) 85-91
25. Lequesne M. Les antiarthrosiques symptomatiques d'action lente: Un nouveau concept thérapeutique?. Rev. Rhum. Mal. Osteoartic. 61 (1994) 75-79
26. Lequesne M., Brandt K., Bellamy N., Moskowitz R., Menkes C.J., and Pelletier J.P. Guidelines for testing slow acting drugs in osteoarthritis. J. Rheumatol. 21 Suppl (1994) 65-73
27. Lequesne M.G. The algofunctional indices for hip and knee osteoarthritis. J. Rheumatol. 24 (1997) 779-781
28. MacAlindon T.E., La Valley M.P., Gulin J.P., and Felson D.T. Glucosamine adn chondroitin for treatment of osteoarthrtis: A systematic quality assessment and meta-analysis. JAMA 15 (2000) 1469-1475
29. Mathieu P. Radiological progression of internal femoro-tibial osteoarthritis in gonarthrosis. Chondro-protective effect of chondroitin sulfates ACS4-ACS6. Presse Med. 31 29 (2002) 1386-1390
30. Mazières B., Loyau G., Menkes C.J., Valat J.P., Dreiser R.L., Charlot J., and Masounabe-Puyanne A. Chondroitin sulfate for the treatment of coxarthrosis and gonarthrosis: A prospective, multicenter, placebo-controlled, double-blind trial with five months follow-up. Rev. Rhum. Mal. Osteoarthric. 59 (1992) 466-472
31. Mazières B., Combe B., Phan Van A., Tondut J., and Grynfeltt M. Chondroitin sulfate in osteoarthritis of the knee: A prospective, double blind, placebo controlled multicenter clinical study. J. Rheumatol. 28 (2001) 173-181
32. Michel B.A., Stucki G., Frey D., DeVathaire F., Vignon E., Bruehlmann P., and Uebelhart D. Chondroitin 4 and 6 sulfate in osteoarthritis of the knee: A randomized, controlled trial. Arthritis Rheum. 52 3 (2005) 779-786
33. Morreale P., Manopulo R., Galati M., Boccanera L., Saponati G., and Bocchi L. Comparison between the anti-inflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J. Rheumatol. 23 (1996) 1358-1391
34. Nasonova V.A., Alekseeva L.I., Arkhangel'skaia G.S., Davydova A.F., Karmil'tseva E.A., Kogan K.M., Mazurov V.I., Rebrov A.P., Riabitseva O.F., Shemerovskaia T.G., Shmidt E.I., Iakushin S.S., et al. Result of the multicenter clinical trial of Structum preparation in Russia. Ter. Arkh. 73 (2001) 84-87
35. Nevitt M.C., Lane N.C., Scott J.C., Hochberg M.C., Pressman A.R., Genant H.K., and Cummings S.R. Radiographic osteoarthritis of the hip and bone mineral density. Arthritis Rheum. 38 (1995) 907-916
36. Nguyen P., Mohamed S.E., Gardiner D., and Salinas T. A randomized double-blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: A pilot study. Cranio 19 (2001) 130-139
37. Pavelka K., Bucsi L., and Manopulo R. Double-blind, dose effect study of oral CS 4&6 1200 mg, 800 mg, 200 mg, against placebo in the treatment of femoro-tibial osteoarthritis. Litera Rheumatol. 24 (1999) 21-30
38. Richy F., Bruyere O., Ethgen O., and Cucherat M. Structural and symptomatic efficacy of glucosamine and chondroïtin in knee osteoarthritis. Arch. Intern. Med. 163 (2003) 1514-1522
39. Rochon P.A., Gurwitz J.H., Cheung C.M., Hayes J.A., and Chalmers T.C. Evaluating the quality of articles published in journal supplements compared with the quality of those publish in the parent journal. JAMA 272 (1994) 108-113
40. Rovetta G. Galactosaminoglycuronoglycan sulfate (matrix) in therapy of tibiofibular osteoarthritis of the knee. Drugs Exp. Clin. Res. 17 (1991) 53-57
41. Tsvetkova E.S., Agababova E.R., and Bogomolova N.A. Cartilage-protective preparations in the therapy of osteoarthritis. Ter. Arkh. 64 5 (1992) 59-60
42. Uebelhart D., Thonar E.J., Delmas P.D., Chantraine A., and Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: A pilot study. Osteoarthritis Cartilage 6 Suppl A (1998) 39-46
43. Uebelhart D., Malaise M., Marcolongo R., DeVathaire F., Piperno M., Mailleux E., Fioravanti A., Matoso L., and Vignon E. Intermittent treatment of the knee osteoarthritis with oral chondroitin sulfate: A one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 12 (2004) 269-276
44. Van Sasse J.L.C.M., Van Romunde L.K.J., Cats A., Vandenbroucke J.P., and Valkenburg H.A. Epidemiology of osteoarthritis: Zoertermeer survey. Comparison of radiologic osteoarthritis in a Dutch population with that in 10 other populations. Ann. Rheum. Dis. 48 (1989) 271-280
45. Verbruggen G., Goemaere S., and Veys E.M. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage 6 Suppl A (1998) 37-38
46. Verbruggen G., Goemaere S., and Veys E.M. Systems to assess the progression of finger joint osteoarthritis and the effect of disease modifying osteoarthritis drugs. Clin. Rheumatol. 21 (2002) 231-243
47. Vignon E., Piperno M., Hellio le Graverand M.P., Mazzuca S.A., Brandt K.D., Mathieu P., Favret H., Vignon M., Merle-Vincent F., and Conrozier T. Measurements of radiographic joint space width in the tibiofemoral compartment of the osteoarthritis knee: Comparison of standing anteroposterior and Lyon Schuss views. Arthritis Rheum. 48 (2003) 378-384
48. World Health Organization. "Guidelines for the Clinical Investigation of Drugs Used in Rheumatic Diseases,". European Drug Guidelines, Series 5. World Health Organization, Regional Office for Europe (1995), European League Against Rheumatism, Copenhaguen 7-24